TITLE

A vaccine that delivers rather than induces antibodies

AUTHOR(S)
Letvin, N. L.
PUB. DATE
November 2009
SOURCE
Gene Therapy;Nov2009, Vol. 16 Issue 11, p1283
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses on the use of a vaccine that delivers antibodies. It refers to a research study in which researchers examined a radically different approach to inducing long-term production of neutralizing antibodies against an AIDS virus. They used adeno-associated virus (AAV) to deliver, directly into the muscles of monkeys.
ACCESSION #
45117851

 

Related Articles

  • Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. Walsh, Stephen R.; Moodie, Zoe; Fiore-Gartland, Andrew J.; Morgan, Cecilia; Wilck, Marissa B.; Hammer, Scott M.; Buchbinder, Susan P.; Kalams, Spyros A.; Goepfert, Paul A.; Mulligan, Mark J.; Keefer, Michael C.; Baden, Lindsey R.; Swann, Edith M.; Grant, Shannon; Ahmed, Hasan; Fusheng Li; Hertz, Tomer; Self, Steven G.; Friedrich, David; Frahm, Nicole // Journal of Infectious Diseases;2/15/2016, Vol. 213 Issue 4, p541 

    Background: Increasing the breadth of human immunodeficiency virus type 1 (HIV-1) vaccine-elicited immune responses or targeting conserved regions may improve coverage of circulating strains. HIV Vaccine Trials Network 083 tested whether cellular immune responses with these features...

  • Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Hansen, Scott G.; Ford, Julia C.; Lewis, Matthew S.; Ventura, Abigail B.; Hughes, Colette M.; Coyne-Johnson, Lia; Whizin, Nathan; Oswald, Kelli; Shoemaker, Rebecca; Swanson, Tonya; Legasse, Alfred W.; Chiuchiolo, Maria J.; Parks, Christopher L.; Axthelm, Michael K.; Nelson, Jay A.; Jarvis, Michael A.; Piatak, Michael; Lifson, Jeffrey D.; Picker, Louis J. // Nature;5/26/2011, Vol. 473 Issue 7348, p523 

    The acquired immunodeficiency syndrome (AIDS)-causing lentiviruses human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) effectively evade host immunity and, once established, infections with these viruses are only rarely controlled by immunological mechanisms. However, the...

  • The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Nelson, Kenrad E.; Clements, Mary Lou; Miotti, Paolo; Cohn, Sylvia; Polk, Frank; Nelson, K E; Clements, M L; Miotti, P; Cohn, S; Polk, B F // Annals of Internal Medicine;9/1/88, Vol. 109 Issue 5, p383 

    Study Objective: To ascertain whether subjects infected with human immunodeficiency virus (HIV) generally develop protective hemagglutination inhibition antibody responses to inactivated influenza vaccines.Design: Prospective study of 104 persons before and after...

  • HIV: Neutralizing antibodies revisited. Bell, Elaine // Nature Reviews Immunology;Jun2002, Vol. 2 Issue 6, p387 

    Discusses research being done on the role of neutralizing antibodies in the development of HIV-1 vaccine. Reference to a study conducted by Maxine Moulard et al published in the 2002 issue of the 'Proceedings of the National Academy of Sciences.

  • Interactions Between Human Plasma Components and A Xenogenic Adenovirus Vector: Reduced Immunogenicity During Gene Transfer. Perreau, Matthieu; Guérin, Marie-Christine; Drouet, Christian; Kremer, Eric J. // Molecular Therapy;Nov2007, Vol. 15 Issue 11, p1998 

    By the time we are adolescents most of us have been in contact with several of the >50 human adenovirus (HAd) serotypes. These common subclinical infections lead to an efficient anti-adenovirus cross-reacting adaptive immunity. During gene therapy, the ubiquitous anti-adenovirus humoral response...

  • Modification of Adenovirus Gene Transfer Vectors With Synthetic Polymers: A Scientific Review and Technical Guide. Kreppel, Florian; Kochanek, Stefan // Molecular Therapy;Jan2008, Vol. 16 Issue 1, p16 

    The chemical modification of adenovirus (Ad) gene transfer vectors with synthetic polymers is a promising strategy for overcoming typical in vivo hurdles associated with Ad-mediated gene delivery. Polymer-modified Ad vectors induce significantly reduced innate immune responses, can evade...

  • Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer. Xiang, Jim; Chen, Yue; Moyana, Terence // Cancer Gene Therapy;Jul2000, Vol. 7 Issue 7, p1023 

    There are currently extensive studies relating to cancer vaccines using tumor cells engineered to express immunogenes and cancer gene therapy using adenovirus (AdV)-mediated gene transfer. In this study, a mouse tumor cell line, VKCK, was cotransfected with genes coding for tumor necrosis...

  • Defining the Protective Antibody Response for HIV-1. Mascola, John R. // Current Molecular Medicine;May2003, Vol. 3 Issue 3, p209 

    The development of an effective HIV-1 vaccine would be greatly facilitated by knowledge regarding the type and quantity of antibodies that are protective. Since definitive immune correlates are established only after a vaccine has been shown to be effective in humans, animal models are often...

  • Progress Towards the Development of a HIV-1 gp41-Directed Vaccine. McGaughey, Georgia B.; Barbato, Gaetano; Bianchi, Elisabetta; Freidinger, Roger M.; Garsky, Victor M.; Hurni, William M.; Joyce, Joseph G.; Xiaoping Liang; Miller, Michael D.; Pessi, Antonello; Shiver, John W.; Bogusky, Michael J. // Current HIV Research;Apr2004, Vol. 2 Issue 2, p193 

    The HIV-1 gp41 envelope glycoprotein mediates fusion of the viral and cellular membranes. The core of the gp41 ectodomain undergoes a receptor-triggered conformational transition forming a trimeric, a-helical coiled-coil structure. This trimer-of-hairpins species facilitates insertion of the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics